ACC 2019 Late-breaking Presentations

The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.19 annual meeting March 16-18, 2019, in New Orleans. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.

ACC also announced the new ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease will be released at ACC.19. This guideline will focus on primary prevention of cardiovascular disease in adults and present recommendations to prevent CVD related to lifestyle factors as well as other factors affecting cardiovascular risk.

For more information on the ACC.19 annual meeting, visit https://accscientificsession.acc.org.

Saturday, March 16
Joint ACC and Journal of the ACC Late-Breaking Clinical Trials I

• The Apple Heart Study: Results Of A Large-scale, App-based Study To Identify Atrial Fibrillation Using A Smartwatch

Saturday, March 16
Featured Clinical Research I

• PANACHE: Safety and Efficacy of Neladenoson Bialanate, a Partial Adenosine A1 Receptor Agonist, in Patients with Heart Failure and Preserved Ejection Fraction. Results from the PANACHE Randomized Controlled Trial
• PIONEER-HF: Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure. Results of the Open-Label Extension of the PIONEER-HF Trial
• Hopeful Heart Trial: Blended Collaborative Care for Treating Heart Failure and Comorbid Depression. 12-Month Primary Outcomes from the Hopeful Heart Trial
• CODIACS-QoL: Randomized Trial of Depression Screening After Acute Coronary Syndromes: Results from Comparison of Depression Identification After Acute Coronary Syndromes-Quality of Life and Cost Effectiveness
• The HoT-PE Study: Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban

Sunday, March 17
Joint ACC/New England Journal of Medicine Late-Breaking Clinical Trials II

• PARTNER 3 Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients: Results of the PARTNER 3 Trial
• Self-Expanding Transcatheter or Surgical Aortic Valve Replacement in Patients at Low Risk of Surgical Mortality
• COAPT Echocardiographic Outcomes: Mitral Regurgitation After MitraClip Implantation in Patients with Heart Failure and Secondary Mitral Regurgitation
• COAPT Quality of Life After Transcatheter Mitral-Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation. Results from the COAPT trial
• Outcomes of Transcatheter Aortic Valve Replacement with Balloon-Expandable Sapien3 Valve in Bicuspid Aortic Stenosis. An Analysis of the STS/TVT Registry

Sunday, March 17
Joint ACC/Journal of the American Medical Association Late-Breaking Clinical Trials III

• AUGUSTUS Trial: An Open-label, 2 x 2 Factorial, Randomized Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist, and Aspirin vs. Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention. Primary Results of the AUGUSTUS Trial
• WRAP-IT: The World-Wide Randomized Antibiotic Envelope Infection Prevention Trial to Reduce Cardiac Implantable Electronic Device Infection
• VIDEO with WRAP-IT presenter Khaldoun Tarakji, M.D. —  VIDEO: Use of an Antibacterial Envelope to Reduce Infections for Pacemakers, ICDs
• POET: Partial Oral Treatment of Left-Sided Infectious Endocarditis — The POET Trial — Long Term Follow-up
• MOMENTUM 3: Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3. Final Analysis of the 1,028 Patient Cohort Outcomes
• CardioMEMS PAS: Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure Patients in Clinical Practice. 1-Year Outcomes from the CardioMEMS Post-Approval Study

Sunday, March 17
Featured Clinical Research II: Interventional

• First Randomized Human Experience with a Ticagrelor Reversal Agent
• The DEFINE PCI Trial: Blinded Physiologic Assessment of Residual Ischemia After Successful Angiographic Percutaneous Coronary Intervention
• ADVANCE Registry: Impact of FFR-CT on 1-Year Outcomes in Patients Evaluated. Lessons from the ADVANCE Registry
• MRUSMI: Sonothrombolysis in ST-segment Elevation Myocardial Infarction (STEMI) Treated with Primary Percutaneous Coronary Intervention. Final Results from the First Randomized Study in Humans
• GLASSY: Impact of Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Stent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-study

Monday, March 18
Late-Breaking Clinical Trials IV

• The CLEAR Wisdom Trial: Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients with Hypercholesterolemia and High Cardiovascular Risk
• CREOLE Study: Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans
• INFINITY: Primary Results of the Intensive versus Standard Ambulatory Blood Pressure Lowering to Lessen Functional Decline in the Elderly Trial
• DECLARE: Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus Based on Ejection Fraction
• REDUCE-IT: Reduction in Total Ischemic Events with Icosapent Ethyl in REDUCE-IT

Monday, March 18
Late-Breaking Clinical Trials V

• The Safety and Efficacy of Femoral Access versus Radial Access for Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction (STEMI) — SAFARI-STEMI Trial
• COACT Trial: Coronary Angiography after Cardiac Arrest
• TREAT Trial: Efficacy of Ticagrelor vs. Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction (STEMI)
• STOPDAPT-2 Trial: One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy vs. Standard 12-Month Dual Antiplatelet Therapy with Clopidogrel After Drug-Eluting Stent Implantation
• SMART-CHOICE: P2Y12 Inhibitor Monotherapy vs. Dual Antiplatelet Therapy in Patients Undergoing Implantation of Coronary Drug-eluting Stents

Monday, March 18
Featured Clinical Research III

• Alcohol AF: Impact of Alcohol Abstinence in Moderate Drinkers with Atrial Fibrillation: Results from the Alcohol-AF Randomized Controlled Trial
• REVEAL: Impact of ADCY9 on Response to Anacetrapib Among 20,000 Participants in the HPS3/TIMI55-REVEAL Trial
• ODYSSEY OUTCOMES: Lipoprotein(a) Lowering by Alirocumab Contributes to Total Events Reduction Independent of Low-Density Lipoprotein Cholesterol in the ODYSSEY OUTCOMES Trial
• DECLARE - TIMI 58: Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE - TIMI 58
• IRAD - Acute Aortic Dissection: Lessons Learned from 9,000 Patients

Other ACC.19 News and Video:

VIDEO: Utilization of PET For Evaluation of Cardiac Sarcoidosis — Interview with Raza Alvi, M.D.,

VIDEO: Key Trends in Electrophysiology — Apple Watch to Detect AF and the CABANA Trial — Interview with Christine Albert, M.D.

Links to Other Recent Late-breaking Trials: 

ACC 2018 Late-Breaking Trials

American Heart Association 2018 Late-breaking Trials

TCT 2018 Late-breaking Cardiovascular Clinical Trials

EuroPCR 2018 Late-breaking Trials in Interventional Cardiology

Heart Rhythm 2018 Late-breaking Studies

SCAI 2018 Late-breaking Clinical Trials